| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 9, 2026 | Expedition Therapeutics Lands $115M Series B |
SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round.
>> Click here for more funding data on Expedition Therapeutics
>> To export Expedition Therapeutic... |
| Aug 6, 2026 | Venture Capital & Startup Funding Roundup, August 6, 2026: Bessemer Venture Partners, Gates Frontier, General Atlantic, Google Ventures, Gradient Ventures, Menlo Ventures, Y Combinator & More | The sprint of venture rounds today underscores a clear theme: autonomy and AI are pulling massive capital — both in the physical world and online. In defense and logistics, startups like Hadrian and Moove drew eye-popping checks ($1.37 bill... |
| Aug 5, 2026 | Executive Exteriors Receives Investment | Executive Exteriors, a Dallas, TX-based provider of specialty roofing and exterior restoration services platform, received an investment of an undisclosed amount.
Backers included Corbel Capital Partners and Sea Pine Equity Partners.
The co... |
| Aug 5, 2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing.
The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| Oct 10, 2025 | Expedition Therapeutics Raises $165M in Funding | Expedition Therapeutics, a San Francisco, CA-based biotech company developing therapies for novel inflammatory and respiratory diseases, raised $165M in Series A financing.
The round was led by Sofinnova Investments and Novo Holdings, with ... |
| Oct 9, 2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| Oct 9, 2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| Expedition Therapeutics | “Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT U... |